Analysts Set Pyxis Oncology, Inc. (NASDAQ:PYXS) Price Target at $10.00

Shares of Pyxis Oncology, Inc. (NASDAQ:PYXS) have been given an average recommendation of “Moderate Buy” by the nine brokerages that are currently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a hold rating and eight have issued a buy rating on the company. The average 1-year price target among analysts that have covered the stock in the last year is $10.00.

Several equities analysts have recently issued reports on the company. Stephens started coverage on Pyxis Oncology in a research report on Friday, November 8th. They issued an “overweight” rating and a $13.00 price target for the company. William Blair cut shares of Pyxis Oncology from an “outperform” rating to a “market perform” rating in a report on Thursday, November 21st. Royal Bank of Canada increased their price target on shares of Pyxis Oncology from $7.00 to $10.00 and gave the company an “outperform” rating in a report on Thursday, November 21st. Finally, HC Wainwright reissued a “buy” rating and set a $7.00 price target on shares of Pyxis Oncology in a research report on Thursday, November 21st.

Insider Activity at Pyxis Oncology

In other news, CFO Pamela Ann Connealy bought 88,850 shares of the stock in a transaction on Tuesday, November 26th. The shares were bought at an average price of $1.96 per share, with a total value of $174,146.00. Following the completion of the acquisition, the chief financial officer now owns 1,199,143 shares in the company, valued at $2,350,320.28. The trade was a 8.00 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 9.80% of the stock is owned by insiders.

Institutional Investors Weigh In On Pyxis Oncology

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Fullcircle Wealth LLC bought a new stake in Pyxis Oncology during the second quarter valued at approximately $40,000. Intech Investment Management LLC purchased a new position in shares of Pyxis Oncology during the 3rd quarter worth $55,000. SG Americas Securities LLC bought a new stake in shares of Pyxis Oncology during the 3rd quarter valued at $58,000. MetLife Investment Management LLC grew its position in shares of Pyxis Oncology by 41.1% during the 3rd quarter. MetLife Investment Management LLC now owns 18,818 shares of the company’s stock valued at $69,000 after acquiring an additional 5,484 shares during the period. Finally, The Manufacturers Life Insurance Company purchased a new stake in shares of Pyxis Oncology in the 2nd quarter worth $65,000. Hedge funds and other institutional investors own 39.09% of the company’s stock.

Pyxis Oncology Trading Up 1.3 %

Shares of NASDAQ:PYXS opened at $1.54 on Friday. Pyxis Oncology has a 12-month low of $1.49 and a 12-month high of $6.85. The stock has a market capitalization of $91.58 million, a price-to-earnings ratio of -1.50 and a beta of 1.00. The stock has a fifty day simple moving average of $2.96 and a two-hundred day simple moving average of $3.31.

Pyxis Oncology Company Profile

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.